Aims: Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are both incretin-based therapies for type 2 diabetes (T2DM) but have distinct efficacy and side effect profiles. We thus performed a systematic review and meta-analysis to compare the effects of GLP-1 agonists to DPP-4 inhibitors on glycaemic control, weight and incidence of adverse events in adults with T2DM. We also sought to determine whether there was any additional effect in switching from DPP-4 inhibitor to GLP-1 agonist.
| INTRODUCTION
Treatment strategies for patients with type 2 diabetes mellitus (T2DM) frequently involve use of more than one anti-hyperglycaemic agent given the progressive nature of this disorder. 1 Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl dipeptidase-4 (DPP- 4) inhibitors are 2 classes of incretin-based therapies that have emerged as potential options when intensifying diabetes treatment.
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Although GLP-1 agonists and DPP-4 inhibitors exert their metabolic effects through the same entero-endocrine axis, they modulate diverse targets within the incretin system, resulting in distinct efficacy and side effect profiles. 8 In this context, there has been growing interest in comparing these 2 classes of anti-diabetic medications as reflected by a series of recent clinical trials [9] [10] [11] ; the data from these individual studies, however, might not be sufficient to provide robust estimates to guide the optimal choice between these agents. As such, a meta-analysis of randomized controlled trials (RCT) comparing GLP- 
| METHODS

| Data analysis
For the meta-analysis of RCTs, we compared the effect of GLP-1 agonists to DPP-4 inhibitors on the following outcomes: (1) glycaemic control, as assessed by changes in HbA1c, (2) weight reduction as assessed by changes in weight, and (3) incidence of the most common adverse events, including drug withdrawal, gastrointestinal adverse effects and hypoglycaemia. We analysed HbA1c and weight as continuous variables and reported absolute differences between arithmetic means before and after interventions. For analyses on the incidence of adverse events, an overall relative risk (RR) was calculated.
We calculated pooled estimates of the mean differences in We used the Cochran Q test to assess heterogeneity between studies, with threshold of a P value lower than 0.1 for significance.
We also did I 2 testing to assess the magnitude of heterogeneity between studies, with values higher than 50% indicating high heterogeneity. 18 We explored heterogeneity between studies using 2 strategies. First, we did pre-planned sensitivity analyses to assess subgroups of studies most likely to yield valid estimates of the intervention based on clinically relevant study characteristics (as described above). Second, using random-effects univariate metaregression models, we assessed clinical and methodological variables that could influence the comparison between GLP-1 agonist and DPP-4 inhibitors with further sensitivity analyses based on these results. Publication bias was assessed by funnel plot of effect size against standard error for every study. Funnel plot asymmetry was tested using Begg and Egger tests, with significant publication bias defined by P value lower than .1. 19 All analyses were performed using Stata 11.0 (Stata Corp, College Station, Texas).
| RESULTS
We identified 647 studies through electronic searches and one study through manual search. Of these, 613 studies were excluded on the basis of title and abstract, leaving 35 studies for further assessment (Figure 1 ). Eighteen studies (n = 4911) met our inclusion criteria and were included in the analysis (Figure 1 ), 13 were RCTs comparing a GLP-1 agonist to a DPP-4 inhibitor 9-11,20-29 and 5 were interventional studies evaluating change in HbA1c and weight following a switch from DPP-4 inhibitor to GLP-1 agonist. [13] [14] [15] [16] [17] ; for 2 studies this information was unclear. 
| Weight
Ten RCTs reported changes in weight in kg (n = 3402). [9] [10] [11] 21, [23] [24] [25] [26] [27] [28] Pooling these data, GLP-1 agonists resulted in greater reduction in weight of −2.15 kg (95% CI −3.04 to −1.27) ( Figure 2B ) as compared to DPP-4 inhibitors. There was statistically significant between-study heterogeneity (I 2 90.9%) and no significant publication bias on Egger test (P = .46)
( Figure S1B ). Noteworthy, Li et al yielded estimates demonstrating the greatest reduction of weight of all studies, falling outside the funnel plot area. 23 In sensitivity analyses excluding the single study in which participants had mean baseline BMI < 27 kg/m 2,23 GLP-1 agonists induced weight loss of −1.54 (95% CI −1.89 to −1.19) as compared to DPP-4 inhibitors. That approach eliminated the between-study heterogeneity (I 2 32.6, P = .16). The results for weight reduction were unchanged on further sensitivity analyses, as described for the HbA1c outcome above (data not shown). Table S2 shows the pooled analysis of adverse events in the 13 RCTs 
| Adverse events
